Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease

Trial Profile

A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2017 Planned End Date changed from 1 Dec 2015 to 1 Jan 2018.
    • 17 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top